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Hypoxia plays an important role in tumour recurrence among head and neck cancer patients.The identification and quantification
of hypoxic regions are therefore an essential aspect of disease management. Several predictive assays for tumour oxygenation status
have been developed in the past with varying degrees of success. To date, functional imaging techniques employing positron
emission tomography (PET) have been shown to be an important tool for both pretreatment assessment and tumour response
evaluation during therapy. Hypoxia-specific PET markers have been implemented in several clinics to quantify hypoxic tumour
subvolumes for dose painting and personalized treatment planning and delivery. Several new radiotracers are under investigation.
PET-derived functional parameters and tracer pharmacokinetics serve as valuable input data for computational models aiming at
simulating or interpreting PET acquired data, for the purposes of input into treatment planning or radio/chemotherapy response
prediction programs.The present paper aims to cover the current status of hypoxia imaging in head and neck cancer together with
the justification for the need and the role of computer models based on PET parameters in understanding patient-specific tumour
behaviour.
1. Introduction
1.1. The Challenge of Hypoxia in Head and Neck Cancer.
Tumour hypoxia remains one of the major causes of treat-
ment failure in solid cancers. Advanced head and neck carci-
nomas are often aggressive and commonly hypoxic, features
that are associated with treatment resistance to both radio-
and chemotherapy and also poor survival [1]. Additionally,
there is evidence that hypoxia limits the effectiveness of
surgery as well [2]. Studies undertaken on head and neck
squamous cell carcinomas have concluded that the median
partial oxygen pressure (pO
2
) is one of the strongest inde-
pendent prognostic factors of both disease-free and overall
survival in these patients, regardless of treatment modality
[1, 3].
Hypoxia was shown to promote angiogenesis and dis-
tant metastases [4, 5] processes that add to the challenge
of managing hypoxic solid tumours. Furthermore, a bell-
shaped relationwas found between themicrovascular density
of head and neck tumours and patient survival, meaning
that both very low and very high concentrations of blood
vessels are associated with poor prognosis [6].Therefore, low
oxygenation status and intensified angiogenesis are equally
linked to treatment failure in head and neck cancer.
As a response to cell loss during treatment, head and neck
tumour cells activate various mechanisms to trigger tumour
repopulation. Similarly to tumour cells, endothelial cells,
which form the lining of blood vessels, have also exhibited
high activity during treatment, leading to regeneration of
microvessel density [7]. The process of tumour repopula-
tion and/or vascular regeneration in head and neck cancer
during radiotherapy creates a vicious circle that is difficult
to interrupt, which is the reason why these occurrences are
commonly associated with treatment failure.
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1.2. Hypoxia as a Promoter of Angiogenesis. Tumours need
oxygen and nutrients to survive and thrive. Tumours that
outgrow their own vasculature lack oxygen supplies and
therefore they start creating their own vascular network to
allow the oxygen transport. In fact, there is experimental
evidence showing that the induction of new blood vessel
formation (i.e., angiogenesis) is activated well before the
tumour outgrows its vasculature [8]. Tumours exceeding the
size of 1mm3 are reliant on blood supply from the newly
created vascular network [9].
Once the angiogenic switch is turned on, new capillaries
start to sprout and generate a whole new vascular network.
Thenewly formed vessels, however, are abnormal looking and
present with leaks, shunts, and blind ends, which can often
be obstructed. These obstructions cause further problems,
as oxygen cannot reach the cells in the affected areas.
Consequently, temporary hypoxia arises which renders the
cells resistant to treatment. This type of hypoxia, also known
as acute hypoxia, is one of the biggest challenges in the man-
agement of malignant neoplasms as they are both spatially
and temporally unstable. In other words, it is impossible to
predict where, when, and for how long a specific tumour
region will be hypoxic. This fact has further repercussions on
treatment planning and delivery, as the hypoxic areas based
on pretreatment images might not coincide with the hypoxic
areas that are present during treatment.
Chronic hypoxia, on the other hand, is more predictable,
as it typically occurs in the core of the tumour and the reoxy-
genation process befalls during fractionated radiotherapy.
1.3. Hypoxia as a Promoter of Distant Metastases. Tumour
hypoxia has been shown to play an essential role in the
promotion of distant metastasis [4] given that the hypoxia-
inducible factor-1𝛼 (HIF-1𝛼) regulates several processes along
the metastatic pathway.
Head and neck cancer metastasizes predominantly to
regional lymph nodes. Both large and small tumours have
the capacity to metastasize given that the primary tumour
expresses the gene for metastatic spread. For instance,
increased gene expression levels of the glucose transporter
protein Glut-1 were found to be correlated with local recur-
rence, regional lymph node metastases, and poor survival
in patients treated for oral squamous cell carcinomas [10].
Similar results were achieved by Zhou et al. in head and
neck cancer patients, indicating a strong relationship between
elevated Glut-1 levels and poor prognosis [11]. However, the
risk of distant metastases was shown to be lower in head and
neck tumours treated with hypoxia modifiers [12].
With today’s technological advances, locoregional control
of several types of cancers, including head and neck, has
improved. The challenge, however, remains controlling the
metastatic spread and thus in themanagement of the systemic
disease. Despite the fact that tumour metastases are the most
common cause of death among cancer patients, methods to
specifically target this process are scarce. Alongside hypoxia,
the metabolic information supplied by PET imaging offers
valuable assessment of tumour metastases. Such information
allows for further treatment planning materialized by either
chemotherapy or targeted radioimmunotherapy [13, 14].
2. Common Assays for Tumour
Oxygenation Status
Over the decades, several methods, including a variety of
imaging modalities, have been trialled to detect hypoxia
and differentiate between the acute and the chronic type,
whenever possible. Hypoxic subvolumes within a tumour
need adequate considerations during treatment planning and
delivery; thus they need to be reliably identified. Due to large
heterogeneities in tissue oxygenation and interpatient varia-
tions [15], hypoxia needs to be individually assessed for each
patient for an accurate target definition and identification of
hypoxic subvolumes for dose painting.
Despite all efforts to develop pretreatment assays to
evaluate the association between the level of hypoxia and
treatment outcome, several predictive assays failed the in
vivo testing [40]. The main objective of predictive assays
for tumour oxygenation status is to select the likelihood of
benefit from the addition of hypoxic cell sensitizers, hypoxic
cytotoxins, or other adjuvant therapies that would lead to an
increased therapeutic ratio in hypoxic tumours. Nowadays,
the importance of microvessel density assessment increases,
together with the development of antiangiogenic agents and
their inclusion in treatment protocols for patients who might
benefit from these therapies.
Both direct and indirect methods have been developed
in order to evaluate and quantify the level of oxygenation in
tumours (Table 1).Themost commonmethods involve (1) the
use of polarographic electrodes, (2) immunohistochemical
staining of hypoxic cells, and (3) a less invasive approach—
PET imaging using hypoxia-specific radiotracers.
It has already been mentioned that microvessel density
is a good predictive factor of treatment outcome in head
and neck cancer [6]. The evaluation of vascular density
represents an indirect method to determine tumour oxy-
genation and is undertaken using tumour biopsies. This
technique originated in the 1960s, when Kolstad showed
that tumours with long intercapillary distances (i.e., with
poor vascular networks) had low oxygenation and higher
probability to recur than tumours with short intercapillary
distances [41]. Microvascular density measurements involve
immunohistochemical techniques for counting of vessels that
were previously labeled with endothelium-specific markers.
One drawback of this method is the lack of information on
acutely hypoxic cell populations. However, vascular density
measurements offer indications regarding chronic hypoxia,
demonstrating that chronically hypoxic cells significantly
contribute to the overall hypoxic fraction and also influence
treatment outcome.
One of the most widely used tools for tumour oxygena-
tion measurements (oxygen tension or pO
2
) is the polaro-
graphic oxygen electrode. The principle of this technique is
based on the polarographic reduction of molecular oxygen at
a platinum electrode, which creates an electric current. The
magnitude of the current depends on the oxygen quantities
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Table 1: Techniques for tumour hypoxia evaluation/measurement.
Technique Characteristics
Polarographic electrode (Eppendorf oxygen
electrode)
Direct and invasive technique involving a fine-needle electrode (cathode) for
tumour hypoxia measurement. The current between the cathode and the
reference electrode is directly proportional to tissue pO2.
Cryospectrophotometry Indirect, histomorphometric assay of oxygen levels in tumour vasculatureassessed on frozen tissue samples.
Microvessel density (angiogenesis assessment)
Indirect way to assess hypoxia using immunohistochemical techniques for
counting blood vessels that were previously labeled with endothelium-specific
markers.
DNA strand break assay (comet assay)
Indirect way to assess tumour hypoxia through DNA strand breaks after
radiation exposure and fluorescent staining, based on the fact that oxic cells get
more damage than hypoxic cells. The DNA fragments detached from the nucleus
resemble the tail of a comet.
Endogenous hypoxia markers
Indirect method to evaluate the hypoxic fraction in tumours. Hypoxia inducible
factor (HIF)-1 alpha, glucose transporter 1 (GLUT 1), and carbonic anhydrase 9
(CA 9) have been identified as proteins, which under hypoxic exposure induce
the transcription of several genes.
Exogenous hypoxia markers
Indirect method to evaluate tumour hypoxia (using biopsies). Exogenous
markers are nitroaromatic compounds (pimo-, miso-, eta-nidazole) which
selectively bind to hypoxic cells.
Oximetry with electron paramagnetic
resonance
Noninvasive and direct method to quantify pO2 in tissue using stable nitroxides
that interact with molecular oxygen.
Blood oxygen level-dependent magnetic
resonance imaging (BOLDMRI)
Noninvasive method for evaluation of hypoxia through correlation of BOLD
signals with pO2.
Positron emission tomography Noninvasive and direct method to evaluate hypoxia via injection ofhypoxia-specific radiotracers.
that reach the electrode. The oxygen electrode that is cur-
rently used in labs is manufactured by Eppendorf-Netheler-
HinzGmbH,Hamburg,Germany.Due to its good correlation
with the clinical outcome, the Eppendorf electrode is still
considered the gold standard in determining the oxygen
tension [42].
One advantage of this technique is that allows quanti-
tative assessment of oxygen distribution levels within the
tumour, without, however, distinguishing between necrotic
and viable cancerous tissues. Amain drawback is linked to the
invasive approach, which limits the technique to superficial
tumours only.
Functional imaging techniques, besides having other
advantages, are noninvasive methods for the assessment of
tumour metabolism and of various tumour-related kinetic
parameters. Nowadays, tumour hypoxia is successfully eval-
uated using such imaging techniques. Positron emission
tomography (PET) and blood oxygen level-dependent mag-
netic resonance imaging (BOLD MRI) are two diagnostic
imaging methods widely used for oncologic investigations.
These two robust techniques are characterized by ease of
use and reliability and are able to assess the heterogeneous
distribution of oxygen with the tumour [43].
BOLD MRI uses paramagnetic deoxyhaemoglobin as
contrast agent (to target red blood cells), which makes
the method sensitive to pO
2
in blood vessels and also in
the neighbouring tissues. However, the technique does not
allow direct measurement of tissue pO
2
. There are various
studies looking into the relationship between pO
2
and BOLD
signal changes to find a reliable correlation between these
parameters [44, 45]. Given that in acute hypoxia the poorly
oxygenated regions extend up to the vasculature, BOLD
MRI seems to be a more sensitive measure of oxygen levels
for perfusion-related hypoxia than for diffusion-dependent
or chronic hypoxia. Due to the large distance between
chronically hypoxic areas and the red blood cells from
existing tumour vessels, BOLDMRI cannot reflect the status
of chronically hypoxic tumour regions [43]. While this
MRI technique does not provide a quantitative measure of
pO
2
, there is experimental evidence showing an association
between variations in tumour oxygenation and changes in
BOLD signals (spin lattice relaxation rate) [44].
Of all the currently existing techniques for in vivo detec-
tion of hypoxia, positron emission tomography is the best
validated and the most used clinical method. PET is a nonin-
vasive, functional imaging technique, which measures the in
vivo distribution of radiolabelled isotopes, after the injection
of a radioactive contrast material. For hypoxia imaging, PET
uses hypoxia-specific radioisotopes which together with 18F-
FDG (fluorodeoxyglucose) offer a complex picture of the
tumour.
3. The Role of PET in Hypoxia
Imaging of Head and Neck Cancer
PET imaging is a valuable tool in assessing oxygenation levels
in tumours for the purpose of treatment planning and also
as a prognostic indicator. It was shown that the information
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Table 2: Trials involving hypoxia-specific PET imaging in head and neck cancer over the last 10 years.
Radiotracer Reference Trial and aim Results
18F-MISO
Rischin et al. 2006 [16]
TROG randomized trial (45 patients)
To determine the association
between tumour hypoxia, treatment
regimen, and locoregional failure in
advanced HNC
18F-MISO-detected hypoxia is
associated with high locoregional failure
in patients not receiving tirapazamine.
Kikuchi et al. 2011 [17]
Clinical study (17 patients)
To evaluate the role of 18F-MISO as a
predictor of treatment outcome in
HNC
Local control after radiotherapy was
significantly lower in patients with high
uptake than in those with low tracer
uptake. Pretreatment scan with
18F-MISO may predict treatment
outcome.
18F-FAZA
Souvatzoglou et al. 2007 [18]
Phase I trial (11 patients)
Feasibility of 18F-FAZA for hypoxia
imaging in HNC patients
Feasible for clinical use and offers
adequate image quality for hypoxia
assessment.
Postema et al. 2009 [19]
Phase I trial (9 HNC patients out of 50
overall cancer patients)
To demonstrate the safety and
biodistribution pattern of 18F-FAZA
in patients with HNC, lung cancer,
gliomas, and lymphomas
Clear uptake of 18F-FAZA was observed
in 6 out of 9HNC patients; good
imaging properties; good
tumour-to-blood ratio. Promising agent
for hypoxia imaging in HNC.
18F-EF3 Mahy et al. 2008 [20]
Phase I trial (10 patients)
To assess the pharmacokinetics,
biodistribution, and metabolism
(324MBq versus 1,134MBq)
Uptake and retention in tumour was
observed; no difference between the
radioactivity groups; no side effects; safe
and feasible.
18F-EF5 Komar et al. 2008 [21]
Phase I trial (15 patients)
To determine the optimal PET
protocol for 18F-EF5 as a hypoxia
imaging agent
Initial 18F-EF5 uptake is governed by
blood flow; later phase uptake is hypoxia
specific (optimal detection time is 3 h
after injection); warranting more study.
18F-HX4 Chen et al. 2012 [22]
Phase I trial (12 patients)
To evaluate the feasibility of HX4
compared with 18F-MISO
HX4 possibly has higher sensitivity and
specificity and shorter
injection-acquisition time (1.5 h) than
18F-MISO
Cu-ATSM
Minagawa et al. 2011 [23]
Phase I/II trial (17 patients)
To evaluate the relationship between
62Cu-ATSM tumour uptake and
chemoradiotherapy
62Cu-ATSM SUVmax greatly differed
between patients with and without
residual disease. 62Cu-ATSM could be a
predictor of tumour response to
treatment.
Grassi et al. 2014 [24]
Preliminary prospective study (11
patients)
To assess the efficacy of pretreatment
64Cu-ATSM as a prognostic factor
and its role as a marker of disease
progression
64Cu-ATSM showed high sensitivity but
low specificity in predicting response to
chemoradiotherapy. There were no
differences between early and late scans.
HNC: head and neck cancer.
provided by PET/CT during therapy leads to changes in
treatment management in up to 40% of the cases [46].
To date, there are several hypoxia-specific PET radioiso-
topes in clinical use or under trial (Table 2). The feasibility
and clinical adequacy of new radiolabelled isotopes are
assessed by means of (1) tumour uptake and retention,
(2) metabolic information supplied, and (3) patient safety.
While several radioisotopes fulfill the clinical criteria as PET
radiotracers, there is need for more comprehensive trials in
order to distinguish in a qualitative manner between the
various compounds currently used.
One category of hypoxia-specific radioisotopes is the
group of radiolabelled nitroimidazole given that nitroim-
idazoles are known to bind selectively to hypoxic cells
where they are reduced [47]. The first labeled nitroimidazole
compound developed for PET detectionwas 18F-MISO ([18F]
fluoromisonidazole) [48]. Pretreatment 18F-MISO uptake
has been shown to be an independent prognostic indicator
following treatment of head and neck cancer (high FMISO
uptakes correspond to low tissue oxygen concentrations,
which usually are indicative of poor response to treatment)
[49]. A comparative study aiming at assessing tumour
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hypoxia in 38 head and neck cancer patients has been
undertaken by Gagel et al. [50] using the polarographic
electrode versus PET imaging with 18F-MISO combined
with 18F-FDG. The group concluded that the noninvasive
PET technique is valid and represents a feasible in vivo
method for determining clinically relevant hypoxia, despite
some of its limitations (such as limited spatial resolution
of PET which can be a challenge when imaging small
tumours).
Beside the quantitative evaluation of hypoxia-specific
radiotracers, there are studies investigating the reproducibil-
ity of the tracer’s uptake in the assessment of hypoxia. A study
undertaken by Okamoto et al. [51] involved eleven head and
neck cancer patients twice scanned with 18F-MISO within
a 48 h interval. The difference between the two maximum
standardized uptake values was 7% while the difference
between the two tumour-to-blood ratios was 9.9%.The study
demonstrated the reliability and reproducibility of 18F-MISO
in regard to tumour hypoxia in head and neck carcinomas.
Another radiotracer that has been intensively stud-
ied in relation to hypoxia is 18F-FAZA (fluoroazomycin-
arabinoside). A comparative study between 18F-FAZA and
18F-MISO undertaken on rat tumours has shown only minor
advantages of the former, consisting of higher tumour to
background and tumour-to-blood ratios due to more rapid
clearance from blood and nontarget tissues [52].
More lipophilic fluorine-based radiotracers have also
been investigated (18F-EF3, 18F-EF5); however clinical find-
ings have shown similar results to those obtained with 18F-
MISO. One of the newer hypoxia-specific PET agents is
18F-HX4 (2-nitroimidazole nucleoside analogue), which was
shown to have better water solubility and faster clearance
than the well-established tracers, presenting also a strong
dependence on tumour hypoxia [53].
Next to fluorine, copper-based radiotracers play an
important role in PET imaging of hypoxic tumour regions.
Lewis et al. have published the first report on the oxygen-
dependent uptake of Cu-ATSM both in vitro and in vivo,
showing that hypoxic cells present with a threefold higher
uptake compared to normally oxygenated cells [54].
While 18F-FDG is not particularly useful for the assess-
ment of hypoxia with static PET imaging, dynamic PET offers
valuable quantitative information on blood perfusion and
also drug pharmacokinetics, which represents an indirect
evaluation of vascular density and functionality [55].
Nevertheless, Mullani et al. [56] have shown that tumour
blood flow measurements can be undertaken from the first
pass of 18F-FDG through the tumour using a simple scan.
This idea is supported by the fact that the initial large influx
of the radiotracer into tissue during the first pass is delivered
as a function of the blood flow to the respective tissue
[55].
While more expertise is needed for dynamic PET image
acquisition and interpretation, the advantage of this approach
is the possibility of following over time the radiotracer’s
metabolism in the region of interest. This allows for a better
differentiation among metabolically dissimilar areas, includ-
ing differently oxygenated regions. Furthermore, dynamic
PET with 18F-FDG gives indications not only on metabolic
changes but also on vascular alterations during fractionated
radiotherapy [57].
It is probably safe to suggest that all radiolabelled com-
pounds trialed so far are valuable instruments, which assist
the clinicians to decide on the most favorable subsequent
treatment, thus bringing the individualized treatment plan-
ning one step closer to clinical implementation worldwide.
Developing clinically robust tools for tumour hypoxia assess-
ment would allow clinicians to choose treatment based
on an individualized, scientific foundation and select those
patients that would benefit from adjuvant therapies in order
to sensitize the tumour to radiation. As stated by Isa et al.
in a review paper published in 2006 [2]: “there is an unmet
need for biological parameters to individualize treatments.”
Several years later, while we have a larger pool of markers
and biological targets available, the above statement remains
valid.
4. Models of Hypoxia Based on PET-Imaging
Computational modelling of PET tracer dynamics is a crucial
step in understanding complex individualised data acquired
during PET imaging. Combined PET/CT image sets provide
functional as well as spatial data from tissue regions that are,
for example, highly metabolically active or relatively low in
oxygen, depending on the specific radioactive tracer (or label)
used. Only through the use of sophisticated models can we
begin to quantitatively analyse PET tracer pharmacokinetics
(PK) within in vivo tumours or normal tissues.
Motivation for this understanding stems from the desire
of clinicians and radiobiologists to utilise specific PET data
to predict tumour behaviour and responses to different
treatment options, such as fractionated radiotherapy. This
utilisation often requires development of further complex
computational models that can read in the PET data and
then apply cell line or tumour specific kinetic processes
and tumour/vessel architecture to simulate proliferation and
treatment induced cell death.
An initial step in interpreting and utilising complex
PET data is to develop a computational model, with the
aims of setting parameters with realistic values (through
comparison with reported biological values) and eventually
the generation of a complete virtual PET image. By these
means, parameters, such as drug uptake, diffusion, and
binding rates for a specific tracer, can be analysed in a model
sensitivity study, withmultiple-parameter solutions and asso-
ciated stochastic uncertainties generated, using the real PET
data as a baseline for comparison. However, model parameter
values may also be patient dependent and at present the field
of tracer modelling is still to reach a consensus on optimal
average population values and their uncertainties.
To be case specific, the model cannot be purely based on
a first principles approach using simple geometry; it requires
information to spatially place important structures such as
blood vessels so that the compound of interest can be accu-
rately simulated in the blood stream and into the target tissue.
This step can add imaging modality related uncertainties or
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other uncertainties if the data is estimated, for example, from
the average vascular densities and diameters from tumour
xenografts.
Two streams of reports exist on the topic of PET tracer
modelling.
(1) Modelling of specific tracer/oxygen dynamics—with
the aim of simulating PET images with results that are
in close agreement with real PET images [26, 58].
(2) Utilisation of PET data within a separate tumour
model—with the aim of making the tumour model
more specific and predictive of response to treatment
[33–35].
The subsections below are separated into the aforemen-
tioned categories, which exist due to the specific aims of
the authors in either studying PET pharmacokinetics (with
a strong emphasis on tumour oxygenation related tracers)
or input and interpretation of voxelized PET data into
computational tumour responsemodels. Models in these two
categories may utilise stochastic and/or analytical methods.
The former may have final objectives of optimising PET
injection and imaging sequencing protocols or investigation
of the impact of acute versus chronic hypoxia on tracer
uptake [26, 58], while the latter may have final aims which
vary due to the treatment modality considered. However
will generally have final objectives related to predicting if
treatment response is enhanced with modified treatment
regimes, compared to the current standard of care. In this
review, the latter topic is discussed in terms of the input of
specific patient PET information into cellular-scale models of
tumour proliferation and radiotherapy response [33–35].
4.1. Modelling PET Pharmacokinetics (PK). Modelling of the
transport of drug molecules through tissue, or “pharmacoki-
netics,” applied to the field of PET radioactive tracers, has
been studied for a number of decades. For the modelling of
tracers that preferentially reduce and bind in the presence
hypoxia or anoxia (i.e., a lack of or no presence of oxy-
genation), early 2- and 3-compartmental analytical model
work was published from approximately the mid-nineteen
seventies and into the first years of the twenty-first century
[59–61].
Compartmental modelling in this respect refers to the
spatial location (it’s “state” may also be specified) of the tracer
as it moves through tissue after injection; that is, the tracer
could exist: (1) in a free state within vessels (within blood
plasma), (2) in the interstitial space, or (3) in the intracellular
space, (i) a free or (ii) a bound (reduced/phosphorylated)
state. Note that the 2-compartment models neglect the
second step. The tracer may be modelled to move from (1)
to (2) via diffusion and/or interstitial fluid convection, while
movement from (2) to (3) requires active transport, facilitated
diffusion, and/or passive diffusion [25, 28].
Tabulated above is a selection of recent reports, where
modelling groups have aimed to predict and better under-
stand PET imaging data for specific tracers (Table 3). These
groupsmay have also performed simultaneous histological or
secondary imaging tests to compare with their primary PET
data set and model results, to validate the placement of well
vascularised, proliferative, or hypoxic tumour subvolumes
[25, 28, 29]. Secondary imaging has in some cases also
enabled realistic (and specific for the tissue being studied)
vessel maps to be incorporated into models for particular
tumour cell lines [30]. This allows the tracer and also oxygen
transport to be simulated in as close a manner (spatially) as
possible to the real situation. In general, model predictions
may be in the form of 2-dimensional virtual PET images
which can be compared to real PET images, or in the form
of parametric solutions for the mathematical model utilised,
that is, the best fit and statistical analysis of all compartment
model coefficients/ parameters.
To summarise the contents of Table 3, analytical com-
partment model work has been extended in recent years to
specific and relevant PET tracer molecules, with statistical
analysis of the best fit of the model parameters being found
to be in good agreement with biological interpretation of
the parameters (e.g., the diffusion rate constant of the tracer
through capillary walls) and with the generated virtual PET
images correlating well with patient and animal model PET
image sets.Thesemodels show that due to the dynamic action
of the tracer molecules, multiple or dynamic PET sequences
are required to best interpret PET data (e.g., to assess hypoxic
tumour regions). Early scans tend to indicate blood vessel
tracer presence, whereas later scans are required to gain infor-
mation about the desired more “final” end points of these
tracers in the target cells. However, specific tracer PK infor-
mation is vital. Modellers as well as clinical PET researchers
may have analysed their results using different terms,
commonly, time-activity-curves [25], standard uptake value
(SUV) with the mean or maximum values analysed for each
voxel [17], or tumour-muscle (TMR) or tumour-blood (TBR)
signal ratios [62]. The latter method normalizes results for
each individual to base-line levels within their own normal
tissue.
Problems in the comparison of virtual PET results with
real data inevitably arise due to noise in the images and
the absence of tracer in tissue regions in which the tracer
has difficulty in reaching, for example, very hypoxic/necrotic
tissue. As a consequence, the functions of tracer concentra-
tion (at any time point) required in models are not likely
to correspond linearly with tissue oxygenation. Rather, the
highest signal is likely to emanate from regions of low to
moderate hypoxia, where transport and binding probability
of the tracer is the highest compared to very low oxygenated
regions where binding is possible but vessel integrity and
density is insufficient. The PET tracer utilised may also
havemultiple biological pathways and reactions; for example,
Cu64[ATSM] has been shown to correlate well with hypoxic
tumour data due to its electrochemical properties, however
“. . .the precise mechanism of Cu-ATSM accumulation remains
largely unknown, as Cu-ATSM accumulation occurs under
normoxic conditions and is strongly influenced by genetic
characteristics that are independent of pO2 status” [29].
Common assumptions made in PK and O
2
diffusion
models due to limitations of complexity, time, computing
power, and available parametric data include the following.
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Table 3: Models from the literature that simulate the pharmacokinetics (PK) of PET tracers to predict and analyse PET scan images.
Reference Modelling Methods Details and Outcomes
(Kelly and Brady
2006) [25]
2-compartment F18[MISO] PK model with
reversible binding, with transport via
diffusion only. 2-dimensional analytical
spatiotemporal model.
Michaelis-Menten techniques were used to model the
conservation of O2 and cap consumption in oxic tissue (pO2
dependent equation). Randomly angled/oriented vessels,
temporal dynamics modelled by changing vessel pressure and
hence flow. Hypoxic tissue: gradual increase in activity then an
accumulation curve. Oxic tissue: activity follows plasma levels
then accumulation curve seen at later stages. Late slope of TAC
curve indicated hypoxia while the beginning represented local
vascular supply. Results compared to pimonidazole stained
tumour sections from clinical colorectal cancer data.
(Wang et al.
2009) [26]
Iterative stochastic optimisation algorithm
to delineate acute and chronic hypoxia in
sequential F18[MISO] and FDG PET in
2-dimensional image maps, with
comparisons to HNSCC clinical data.
Simulated images (known hypoxic regions) as well as sequential
PET Data from 14 male HNSCC patients analysed assuming
chronic (Gaussian histogram of number of voxels versus SUV)
hypoxia remained constant while acute hypoxia (Poisson
histogram) was varied. Normalisation methods forced the
volume of hypoxia to be the same in both time-point scans;
however the location of acute hypoxia varied. Image registration
and resolution issues are discussed. Model predicted Gaussian
chronic hypoxia distributions well in the generated images (𝑟2 =
0.93). Good fit found (13/14 cases), with acute hypoxia described
well by a Poisson curve (11/14 cases) with an average of 34%
(acute hypoxic volume). Suggested a third scan to increase
temporal hypoxia information. 4mm PET pixel size issue
accounted for using power law distribution of chronic versus
acute hypoxia within each pixel.
(Bartlett et al.
2012) [27]
Two varieties of 2-compartment,
3-rate-constant models applied to
F18[MISO] PET images of human prostate
tumour xenografts in rats.





while the other did not. Intratumoural pO2 was assessed using a
robotic driven probe in tumour versus plasma regions of the
animal’s tumour mass. Pimonidazole and perfusion Hoechst
33342 staining also analysed. Kinetic voxelised modelling (of
parameter 𝑘
3
) identified hypoxia with greater accuracy than





fitting was effective in controlling noise in the trapping rate
constant, 𝑘
3
, without introducing bias. No obvious pO2 cutoff
for isolating hypoxic and nonhypoxic volumes (3.4mmHg
applied) however noise of approx. 0.7mmHg in measurement
technique.
(Gu et al. 2012)
[28]
3-compartment F18[FLT] PK model (3 rate
constants) applied to a separate GBM
growth model utilising spatial MR data and
considering invasion, hypoxia, necrosis, and
angiogenesis.
Voxels assigned “cell density” values with hypoxic versus oxic
percentages (e.g., 70 versus 30%) generated. Model simulated
the dynamic clinical-scale imaging process in terms of noise and
reconstruction uncertainties of PET. Clinical GBM patient data
used for comparison, with patient specific virtual PET scans
generated with no statistical difference to real hypoxic tumour
image sets. Model could predict and distinguish hypoxic cell
hyperactivity versus hyperdensity on the PET image.
(McCall et al.
2012) [29]
TACs derived from mean tissue activity
concentration functions for Cu64[ATSM]
(Ct) in HNSCC and muscle and compared
to venous input functions (Cp).
Tracer dynamics studied in HNSCC (FaDu) xenografts in rats
and analytical parameters of the model fitted to generated
results matching real PET data. Influx-constants (Ki) calculated
by analysis of Patlak plots of Ct/Cp ratios versus normalized
time integrals of Cp. PET mean data analysed from 1min up to
18 hours after injection. Distribution volumes (𝑉
𝑑
) calculated.
High tumour to muscle uptake ratios found (4 : 1 tumour to
muscle ratio at 20min). No Cu64[ATSM] correlation to
pimonidazole hypoxia staining (early or late). Cu dynamics are
not only pO2 dependent, more study recommended. Early
uptake of tracer in tumour at 1min found followed by slower
but steady increase, while muscle signal increased quickly then
plateaued. Wash out rates in tumour and normal tissue difficult
to define.
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Table 3: Continued.





O2 kinetic and F
18[MISO] tracer PK model
simulating 2-dimensional virtual PET maps,
based on blood vessel maps from human
HNSCC xenografts stained for endothelial
structures
Xenografts were utilised to derive 2D vessel maps (∼3% vascular
fraction) and an explicit pO2-dependent binding rate,𝐾(𝑃).
Oxygen and tracer flux across vessel walls, 𝐽
𝑇
, assumed
proportional to the concentration differences on the intra- and
extravascular side. Tracer moved via diffusion. Irreversible
binding rate modelled as dependent on pO2 only. Nonlinear
Michaelis-Menten oxygen consumption versus pO2 tension.
Individual time-point data did not show correlation with real
data (2.5mmHg threshold for each voxel with median pO2 in
each voxel assessed); however, ratios of 0–15min versus 4-hour
data had significant outcomes. Four-hour data did correlate but
not as well as ratio data. From 2011: binding versus pO2 function
described with steep initial increase (<0.5mmHg). Simulated
local TACs share characteristics with clinical PET TACs hence it
may be possible to measure perfusion from early dynamic PET.
Alternative tracer dynamics (faster clearance) also simulated
with earlier time point PET scans predicted optimum, although
free-tracer signals limit earlier time feasibility.
(Liu et al. 2014)
[32]
F18[FLT] 2- and 3-compartment PK models
compared for HNSCC clinical PET images,
incorporating diffusion as well as convection
transport of the tracer.
A comprehensive statistical analysis of the PK model is
reported. “EM-BIC” clustering methodology described, and
model used to analyse raw PET images and reduce noise and
hence uncertainty in the rate constant parameters derived.
Model results compared to 10 × 1-hour dynamic HNSCC
clinical PET data sets, with the 3-compartment (6 rate
constants) “3C6K” model best fitted patient data.
[TAC: time activity curve; HNSCC: head and neck squamous cell carcinoma; GBM: glioblastoma multiforme; PK: pharmacokinetic; pO2: partial pressure of
oxygen; SUV: standard uptake value].
(1) Homogeneous cellular density, diffusion, and con-
sumption coefficients, which is not the case in a
heterogeneous tumour.
(2) The use of static histological data used to generate
vessel maps and hence the assigning of O
2
in 2- or
3-dimensional maps does not reflect acute hypoxic
dynamics, which can be overcome by specifically
modelling O
2
kinetics [30] with realistic temporal
fluctuations in O
2
supply and realistic cellular O
2
consumption [28].
(3) The lack of machine specific corrections (dead time,
decay rate, noise, scatter, attenuation correction, and
time-of-flight) and reconstruction related random
and systematic uncertainties, considered however by
some groups [28, 33] and specifically investigated in
terms of attenuation correction based on X-ray CT
data [63] or segmentation of emission images and in
terms of partial volume effects [64].
Neglected in Table 3 are reports from authors addressing
oxygen and/or tracer dynamics using multimodality imaging
techniques without a “modelling” approach (see Section 3).
These reports can add valuable data in terms of correlations
between anatomy, tracer, and oxygenation in space and time,
for example, the work of Cho et al., who have combined
PET (F18[MISO]), MR, H&E, pimonidazole, and F18 autora-
diography techniques in a prostate xenograft tumour model
to analyse necrosis, hypoxia, and well perfused tissue and
to confirm the validity of the different imaging modalities
in identifying these tumour subvolumes [37]. Cho et al.
[37] found that combined hypoxia and perfusion data could
predict outcome but could neither alone correlate well with
regions of perfused tissue (as indicated by early PET uptake).
4.2. Utilisation of PET Data in Treatment Response Models.
As the previous section has shown, there are many factors
that influence final PET image voxel intensities.These factors
reduce down to being related to both tracer pharmacokinetics
and specificity or machine intrinsic spatial resolution limits.
When desiring to take this data and use it for input into
computational tumour models, these factors must also be of
paramount concern. The tumour model, if at the cellular-
scale, will require a suitable scaling paradigm to convert data
at the mm scale down to an approximate 10–50𝜇m scale and
also method of converting the PET signal intensity assigned
to each tumour voxel or “cell” into an actual parameter value,
such as pO
2
if, for example, oxygenation data has been the
intention of the PET scan.
Stochastic methods utilising probability distributions
may be useful for both of these tasks. Models capable of
simulating tumours at the cellular level with real tumour-
like proportions are challenging, hence limited number of
papers reviewed.This topic is however at a stage of expansion
and it is foreseen that more groups will report of their
modelling experiences in the field of PET data tumour
response modelling within the present decade. This will
be aided by not only computing power increases, but also
the demand by clinicians and the public to use currently,
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Table 4: Stochastic tumour models utilising PET oxygenation data to predict the efficacy of nonstandard treatment solutions.
Reference Modelling methods Details and outcomes
(Toma-Das¸u et al.
2009) [33]
F18[MISO] and Cu[ATSM] distribution
functions modelled in a 108 cell tumour
growth and O2 transport model followed by
uniform or central boost RT.
Tracer binding versus pO2 functions used (higher uptake at
intermediate O2 for Cu) to generate tracer uptake maps for each
tracer on a 2D slice of heterogeneous spherical tumour.
Convolution function used to describe finite resolution of the
imaging modality. Local temporal changes in cellular O2
accounted for. Virtual image maps generated to predict LQ
survival and Poisson tumour control using 2 different circular
dose distributions with central boost doses. Redistribution of
dose (same integral dose but hotter in the centre) was possible
for each tracer without decreasing the target tumour control
(90%).
(Titz and Jeraj 2008,
Titz et al. 2012)
[34, 35]
Simulating effects of antiangiogenic
treatment using F18[FDG], F18[FLT] and
Cu61[ATSM] PET data in a tumour
proliferation and therapy model
(2008—where RT is modelled as the
treatment modality) with an added vascular
and PET/drug PK/PD component (open
2-compartment) (2012).
BvMb plasma concentration-time-profiles cbev(t) utilised, with
model parameters adapted to population-based values (e.g.,
MVD to determine BvMb PD). A linear relationship between
VEGF expression and endothelial cell (EC) proliferation used.
Nonnormal distributions manipulated the raw data O2 PET data
(∼4mm pixels) for cellular level input to generate 2D
oxygenation maps considering multiple diameters and angles of
the vessels. 8HNSCC PET scans used (phase 1 trial data), before
and after RT for input and comparison to model predictions. A
decrease in SUVs (i.e., reduction in vasculature) after BvMb
agreed with follow-up PET. Increase in hypoxia due to BvMb
observed, peaking at week 2 after treatment, but decreasing with
increasing baseline levels of hypoxia and increasing CCT. Due
to pO2 and proliferation interdynamics, simulations could
provide estimates of optimal drug administration times (i.e.,
every 2 or 3 weeks). Expansion planned for the use of
voxel-based kinetic parameters to model drug uptake more
precisely and vessel “remodelling” in response drugs.
[PD: pharmacodynamic; CCT: cell cycle time; BvMb: bevacizumab].
or soon-to-be, available individualised PET data for specific
(not only region of interest contouring) purposes during
treatment planning.
Two reports from stochastic tumour modelling groups
are summarised in Table 4. These groups have developed
models of varying complexities, including treatment response
modelling, with discussions about how the previously pre-
sented limitations and issues have been considered.
To expand upon the work that has been performed to
estimate modified treatment responses, Table 5 has been
included to further highlight efforts that have been made
to consider tumour model predictions within clinical radio-
therapy treatment planning systems (TPS) dose distributions,
where the plan has either been delivered to real patients or
the distributions analysed for their feasibility in terms of
deliverability and toxicity.
A thorough overview of the process of gaining infor-
mation from PET/CT and using it to optimise pre- and
midtherapy planning processes was published in 2013 [65].
The authors concentrate on how hypoxia related information
can be obtained and used in the planning process, from
interpretation of PET data to final planning and prescriptions
for radiotherapy. Dose painting (DP) methods, for example,
methods to “redistribute dose” to the most radioresistant
HTVs or escalating/boosting the dose to HTVs above the
standard uniform dose prescription, are discussed along with
many of the current challenges that requiremore research and
validation. Indeed, modern IMRT techniques are confirmed
here as being capable of delivering complex nonuniform dose
gradients with a resolution similar to that of PET images
which could in theory deliver a gradient of prescription doses
to subvolumeswith different severities of oxygen deprivation.
Geets et al. remind us of the difficulties faced in imple-
mentation arising not only from intrinsic noise, blur, and
partial volume effects in PET data, but also in the use of a suit-
able tracer that is specific and can reach the hypoxic tumour
environment (i.e., low probability of being bound/reduced
due to other microenvironmental factors such as low pH)
and the use of suitable scan time protocols. References
are provided from groups reporting workable solutions to
uncertainties arising due to the image acquisition itself;
however, as the reports in Table 3 confirm, the latter issues
may not be easily overcome without future tracer specificity
research and scanning at multiple time points after injection.
F18[FAZA] ismentioned as showing promise as good hypoxia
tracer; however all tracers did [65] and continue to have
issues, with no compound standing out as superior.
This report also discusses the issues of converting
oxygenation information into radioresistance estimates
and hence prescription requirements, in order to achieve
increased tumour control. These are nontrivial challenges,
as both functions of converting pO
2
to cell death probably,
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Table 5: Application of model predictions to clinical radiotherapy dose distributions to increase tumour control in hypoxic tumours.
Reference Treatment/Model Methods Details and Outcomes
(Thorwarth and Alber
2008) [36]
F18[MISO] PET/CT performed on 15HNC
patients, with mid-RT scan after 20Gy and
with total dose of 70Gy. DP strategies
investigated.
Hypoxia and well as perfusion parameters combined could
predict for RT outcomes, but neither alone (similar to study
by Cho et al. 2009) [37] Model was calibrated using hypoxia
and perfusion outcomes from this patient set and was
designed to be used to predict optimal dose escalation
factors to radioresistant HTVs. DP found feasible without
increased toxicity to normal tissues.
(Choi et al. 2010) [38]
IMRT dose escalation to the HTV (from 2.4 to
2.6–3.6Gy/30 fractions) planned for 8HNSCC
patients after F18[MISO] PET/CT (4 hours post
injection). ECLIPSE TPS and 6MV X-rays
beams utilised.
Tumour/cerebellum activity ratio of 1.3 used as a cut-off
value for HTV definitions. Dose escalation to at least 2.6Gy
to the HTV found feasible for 6/8 patients, where the HTV




IMRT optimisation performed using a research
TPS to plan dose distributions for various
scenarios of HTV evolution during RT. Data
from 7HNSCC patients after F18[MISO]
PET/CT (120–160min post injection) applied.
HTV aim (dynamic pO2 case) of increasing
dose from 60 to 77Gy.
PET signal to uptake (and hence pO2 and then
radiosensitivity) data conversion used a maximal pO2 level
of 60mmHg and analytical formula. Model provides an
objective method to set minimum doses to hypoxic regions
to counteract increased radioresistance in individual
tumours, without comprising tumour control, that is no
decreasing non-hypoxic volume doses below current
clinical doses.
[DP: Dose Painting; HTV: Hypoxic Target Volume; IMRT: Intensity Modulated Radiotherapy; TPS: Treatment Planning System; RT: Radiotherapy].
that is, radiosensitivity, or cell death to tumour control are
nonlinear and dependent on patient specific parameters. The
authors remind us that chronic hypoxia remains the focus
of the discussed techniques, as opposed to acute/transient
hypoxia which may alter in oxygenation faster than the time
a PET scan can be acquired and analysed (or radiotherapy
planned/delivered). Logistical noteworthy challenges are
discussed, for example, the set-up accuracies required,
volume expansion protocols for adding margins onto regions
of interest nonuniform dose prescription, and how often to
rescan during therapy to balance workload of scanning and
replanning with the timing of substantial biological change
and hence improvement in therapeutic ratio if the plan is
altered.
5. Conclusions
Tumour hypoxia remains one of the major causes of treat-
ment failure in head and neck cancer. By promoting angio-
genesis as well as distant metastases, hypoxia becomes an
important treatment target. In order to increase the ther-
apeutic ratio it is crucial to identify and to quantify the
hypoxic subvolumes. To date, PET-based molecular imaging
is the most commonly employed technique applied for this
purpose.
The use of computational models for treatment assess-
ment and prediction is fast growing. Whether simulated or
actual PET data has been applied to a tumour response
model, overall the current literature suggests that targeting
radioresistant hypoxic tumour subvolumes using complex
dose gradients or even simpler boost doses is feasible using
modern radiotherapy techniques. Research has also shown
that toxicity need not be compromised if careful planning
is performed, with a possible solution being not to increase
the integral dose but rather decrease the prescription to well
oxygenated regions and increase it to chronically hypoxic
areas. This is still to be confirmed in randomised clinical
trials.
As it stands currently, all the signs point to hypoxia
dose painting as being feasible to tackle notoriously hypoxic
tumours, such as head and neck carcinomas. To further
improve, the field moves into requiring individual tracer
pharmacokinetic information/analysis so that PET data can
be accurately interpreted and then utilised appropriately
to predict optimal treatment plans and overall outcome
improvement.
Health institutions will need to encourage and support
multidisciplinary research and prioritize resources to make
the use of functional PET information feasible, as assess-
ing the dynamic changes of the tumour characteristics at
a number of time points after PET injections and then
at multiple intervals throughout radiotherapy will always
inevitably be highly resource intensive.This will be especially
true during the learning phase as this technique is translated
from research into the routine clinical environment. Compu-
tational pharmacokinetics and tumourmodels will be vital in
this translation process.
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